KRASG12D|Mutated Metastatic Colorectal Cancer

A retrospective analysis of the prognostic impact of KRAS G12D ...

105Background: KRAS is an oncogene that is mutated in about half of all metastatic colorectal cancers (mCRC). Recently, a novel therapy targeting KRAS G12C ...

KRAS inhibition in metastatic colorectal cancer – An update - PMC

KRASG12D inhibitors: KRASG12D mutation is present in 12% of metastatic CRC and is the most common KRAS mutation in CRC. The switch II pocket of KRASG12D ...

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Colorectal cancer is one of the world's most prevalent and lethal cancers. Mutations of the KRAS gene occur in ~40% of metastatic colorectal ...

The current understanding on the impact of KRAS on colorectal cancer

Compared with wild-type KRAS and codon 12 mutant, patients with KRAS mutations at codon 13 are more likely to have metastasis to more than 2 organs, with higher ...

Setting Off on the Mission to Target KRAS in Colorectal Cancer

... KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet 6:116, 2015. Go to Citation. Crossref · PubMed · Google ...

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with ...

KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C ...

Role of oncogenic KRAS in the prognosis, diagnosis and treatment ...

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated ...

Adagrasib with or without Cetuximab in Colorectal Cancer with ...

Adagrasib had antitumor activity in heavily pretreated patients with metastatic colorectal cancer with mutant KRAS G12C, both as oral monotherapy and in ...

Review Strategies to tackle RAS-mutated metastatic colorectal cancer

RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to ...

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with ...

In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 ...

Impact of KRAS G12 mutations on survival with trifluridine/tipiracil ...

Abstract. Background. In metastatic colorectal cancer (mCRC), KRAS mutations are often associated with poorer survival; however, the prognostic ...

Frequency of Specific KRAS Mutations, and Their Impact on ...

Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the ...

Targeting KRAS in metastatic colorectal cancer: current strategies ...

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts ...

Clinical features associated with NeoRAS wild-type metastatic ...

NeoRAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC).

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Here, we review the development of KRAS targeted treatment in CRC, mechanisms of resistance and potential combination strategies to improve efficacy.

Mutations matter: An observational study of the prognostic and ...

BackgroundAbout half of metastatic colorectal cancers (CRCs) harbor Rat Sarcoma (RAS) activating mutations as oncogenic driver, ...

Codon-specific KRAS mutations predict survival benefit of trifluridine ...

Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/ ...

Understanding the KRAS Mutation in Colorectal Cancer - Healthline

And research shows it's linked to treatment resistance and worsened survival rates. If you receive a colorectal cancer diagnosis, KRAS mutation ...

Real-World Study of Characteristics and Treatment Outcomes ...

G12C mutations and an unmet medical need in this population. KRAS p.G12C, metastatic colorectal cancer, retrospective. Issue Section:.

KRAS G12C mutation in metastatic colorectal cancer: a new target

Researchers continue to explore the clinical implications and efficacy of KRASG12C inhibitors. We are indeed in the golden era of direct KRAS inhibitors.